Cross-Country Transportation Efficacy and Clinical Outcomes of Preloaded Large-Diameter Ultra-Thin Descemet Stripping Automated Endothelial Keratoplasty Grafts.


Journal

Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186

Informations de publication

Date de publication:
Jan 2019
Historique:
pubmed: 13 11 2018
medline: 12 1 2019
entrez: 13 11 2018
Statut: ppublish

Résumé

To evaluate the clinical outcomes of preloaded large-diameter ultra-thin grafts for Descemet stripping automated endothelial keratoplasty (UT-DSAEK) after cross-country shipment. A laboratory study in an eye bank and a clinical cohort study in an academic tertiary care center were performed. UT-DSAEK (9.5 mm diameter) grafts (n = 7) were prepared, loaded into a commercial device (iGlide; Eurobio, Les Ulis, France), preserved for 4 days at room temperature in transport medium, and analyzed. In a retrospective study, preloaded tissues (n = 39) for clinical use were prepared, transported from Italy to the United Kingdom, and surgically delivered into the eyes of patients undergoing UT-DSAEK. Central and peripheral endothelial cell density (ECD) and viability were measured before and after loading and storage of the grafts in the laboratory study. Clinically, best-corrected visual acuity, ECD before and at final follow-up, dislocation rate, primary graft failure, and surgical time were recorded. In the laboratory study, postcut central graft thickness was 93.3 ± 17.2 μm. ECD and cell mortality did not change significantly before and after preservation (P = 0.8). Cell loss after 4 days of preservation was 1.7% ± 1.6%. Clinically, 39 eyes of 39 patients at final follow-up showed a mean central graft thickness of 88 ± 22 μm and a best-corrected visual acuity of 0.34 ± 0.24 logMAR. Nine of 39 cases (23%) needed rebubbling, and 28% cell loss was observed at final follow-up. Large-diameter UT-DSAEK grafts can be prepared and preloaded in the eye bank using the iGlide and transported to the surgical center facilitating surgery for patients undergoing UT-DSAEK, potentially reducing tissue wastage, surgical time, and costs related to surgery.

Identifiants

pubmed: 30418273
doi: 10.1097/ICO.0000000000001777
doi:

Substances chimiques

Culture Media 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-34

Auteurs

Mohit Parekh (M)

International Center for Ocular Physiopathology, The Veneto Eye Bank Foundation, Venice, Italy.
Institute of Ophthalmology, University College London, London, United Kingdom.

Alessandro Ruzza (A)

International Center for Ocular Physiopathology, The Veneto Eye Bank Foundation, Venice, Italy.

Bernhard Steger (B)

Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria.

Colin E Willoughby (CE)

School of Biomedical Sciences, Ulster University, Northern Ireland, United Kingdom.

Salwah Rehman (S)

Department of Ophthalmology, St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.
Department of Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom.

Stefano Ferrari (S)

International Center for Ocular Physiopathology, The Veneto Eye Bank Foundation, Venice, Italy.

Diego Ponzin (D)

International Center for Ocular Physiopathology, The Veneto Eye Bank Foundation, Venice, Italy.

Stephen B Kaye (SB)

Department of Ophthalmology, St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.
Department of Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom.

Vito Romano (V)

Department of Ophthalmology, St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.
Department of Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom.
Instituto Universitario Fernandez-Vega, Universidad de Oviedo and Fundacion de Investigacion on Oftalmologica, Oviedo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH